Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk Management Plan: Four Levels, From Labeling To Restricted Access

Executive Summary

FDA is proposing four levels of risk management programs for prescription drugs and biologics in a "Risk Management Programs" draft 1concept paper released March 6

You may also be interested in...



FDA Evaluation Of Risk Management Plans And “Tools” Needed, PhRMA Says

FDA should undertake a review of all current and past risk management plans and "tools" to document their effectiveness, PhRMA says

FDA Evaluation Of Risk Management Plans And “Tools” Needed, PhRMA Says

FDA should undertake a review of all current and past risk management plans and "tools" to document their effectiveness, PhRMA says

FDA Moves Ahead With Adverse Event Data-Mining; “White Paper” Out Soon

An FDA-PhRMA working group is finalizing a "white paper" on data mining as a tool in postmarketing safety surveillance

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel